Xenon Pharmaceuticals/XENE

$39.82

-4.35%
-
1D1W1MYTD1YMAX

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).

Ticker

XENE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Ian Mortimer

Employees

251

Headquarters

Vancouver, Canada

XENE Metrics

BasicAdvanced
$3.13B
Market cap
-
P/E ratio
-$2.73
EPS
1.18
Beta
-
Dividend rate
$3.13B
1.18366
$50.99
$27.99
368.48K
23.648
-21.22%
-22.12%
-21.86%
3.37
3.373
-100%
-40.12%

What the Analysts think about XENE

Analyst Ratings

Majority rating from 18 analysts.
Buy

Price Targets

Average projection from 15 analysts.
45.91% upside
High $65.00
Low $50.00
$39.82
Current price
$58.10
Average price target

XENE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-44.7M
-7.64%
Profit margin
0%
-

XENE Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 15.7%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.63
-$0.72
-$0.73
-$0.64
-
Expected
-$0.62
-$0.70
-$0.77
-$0.76
-$0.66
Surprise
1.35%
3.25%
-5.7%
-15.7%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Xenon Pharmaceuticals stock?

Xenon Pharmaceuticals (XENE) has a market cap of $3.13B as of April 18, 2024.

What is the P/E ratio for Xenon Pharmaceuticals stock?

The price to earnings (P/E) ratio for Xenon Pharmaceuticals (XENE) stock is 0 as of April 18, 2024.

Does Xenon Pharmaceuticals stock pay dividends?

No, Xenon Pharmaceuticals (XENE) stock does not pay dividends to its shareholders as of April 18, 2024.

When is the next Xenon Pharmaceuticals dividend payment date?

Xenon Pharmaceuticals (XENE) stock does not pay dividends to its shareholders.

What is the beta indicator for Xenon Pharmaceuticals?

Xenon Pharmaceuticals (XENE) has a beta rating of 1.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Xenon Pharmaceuticals stock price target?

The target price for Xenon Pharmaceuticals (XENE) stock is $58.1, which is 45.91% above the current price of $39.82. This is an average based on projections from 15 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Xenon Pharmaceuticals stock

Buy or sell Xenon Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing